Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

2012281 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 13, Issue 9, pp. 879-886

Field-Weighted Citation Impact: 14.97